18 January 2017 - A small Australian drug developer is one stock rising thanks to Donald Trump’s presidency, with two of its key investors closely linked to the 45th president of the United States.

Innate Immunotherapeutics, which is developing a drug to treat multiple sclerosis, lists New York congressman Chris Collins — the congressional liaison to Mr Trump’s transition team — as its largest shareholder and a ­director.

Mr Trump’s nomination for secretary of health and human services, representative Tom Price of Georgia, is also a shareholder in the Sydney-based ­company.

Read The Australian article